Key result
Antiinflammatory therapies for HF show limited success, highlighting the need for targeted treatments avoiding broad immunosuppression.
Why the study?
Despite increasing knowledge about inflammation in heart failure, the clinical success of antiinflammatory and immunomodulatory therapies remains limited.
This review highlights the complexity of inflammation in heart failure and calls for targeted immunomodulatory therapies that avoid nonspecific immune suppression.
Answers are grounded in this paper and cite their sources.
Current antiinflammatory therapies warrant continued caution in heart failure; leaves open targeted immunomodulation avoiding nonspecific suppression.
Intensive research over the last 3 decades has unequivocally demonstrated the relevance of inflammation in heart failure (HF). Despite our current and ever increasing knowledge about inflammation, the clinical success of antiinflammatory and immunomodulatory therapies in HF is still limited. This review outlines the complexity and diversity of inflammation, its reciprocal interaction with HF, and addresses future perspectives, calling for immunomodulatory therapies that are specific for factors that activate the immune system without the risk of nonspecific immune suppression.
No takes yet. Share an insight, caveat, or question.
Linthout et al. (2019) conducted a review in Heart failure. Antiinflammatory and immunomodulatory therapies was evaluated. Antiinflammatory and immunomodulatory therapies for heart failure have shown limited clinical success, highlighting the need for specific treatments that avoid nonspecific immune suppression.
Synapse has enriched 10 related papers. Consider them for comparative context: